Page last updated: 2024-12-05

lg 100268

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3922
CHEMBL ID288436
SCHEMBL ID301213
MeSH IDM0250476

Synonyms (58)

Synonym
BIDD:PXR0022
6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-nicotinic acid
cd-3127
bdbm50032671
gtpl2808
153559-76-3
lg 100268
3-pyridinecarboxylic acid, 6-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl)-
6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
lg2 ,
lg-100268
DB01941
lg100268
lg 268
6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)nicotinic acid
lg268
dtxsid90165354 ,
lg-268
CHEMBL288436 ,
6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
agn 192620
uvu4x1103p ,
alrt 268
cd 3127
unii-uvu4x1103p
FT-0670785
NCGC00242489-01
lgd-100268
alrt-268
lgd 100268
3-pyridinecarboxylic acid, 6-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl cyclopropyl)-
sc-211737 ,
lgd-1268
agn-192620
lgd 1268
6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl]-3-pyridinecarboxylic acid
SCHEMBL301213
MLS006010752
smr004701705
AKOS025394395
lg100268, >=98% (hplc)
J-009027
NCGC00242489-02
6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]nicotinic acid
SLXTWXQUEZSSTJ-UHFFFAOYSA-N ,
Q27080267
lg-100268; lg 268; cd 3127
A14127
lg 100268 ; lg-100268
BCP08283
D95592
6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)cyclopropyl]nicotinic acid
mfcd01758574
SY274278
A935146
CS-0005972
HY-15340
6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)nicotinicacid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"In two independent studies, obese Zucker rats were dosed orally once daily for 14 days with one of the following treatments: LG 100268 (20 mg/kg), LG 100324 (20 mg/kg), BRL 49653 (3 mg/kg) or vehicle."( Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Cawthorne, MA; Crombie, DL; Heyman, RA; Hislop, DC; Liu, YL; Sennitt, MV, 2000
)
0.51
" The 5 h fasted plasma insulin concentration was significantly lower in the rexinoid-treated groups and the terminal insulin level (at the end of the clamp) tended to be lower in all treated groups compared with animals given the dosing vehicle."( Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Cawthorne, MA; Crombie, DL; Heyman, RA; Hislop, DC; Liu, YL; Sennitt, MV, 2000
)
0.31
" We also show that it is not necessary to administer Arz and 268 continuously during tumor progression to prevent cancer in the rat model because dosing of these drugs in combination for relatively short periods, each followed by drug-free rests, is highly effective."( The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
Berchuck, A; Heyman, RA; Krajewski, S; Lamph, WW; Liby, K; Reed, JC; Rendi, MH; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency16.62610.001310.157742.8575AID1259255
tyrosine-protein kinase YesHomo sapiens (human)Potency61.34940.00005.018279.2586AID686947
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peroxisome proliferator-activated receptor gammaRattus norvegicus (Norway rat)Ki1.00005.59005.59005.5900AID157284
Retinoic acid receptor alphaHomo sapiens (human)Ki2.14750.00100.94856.5000AID199194; AID199977
Retinoic acid receptor betaHomo sapiens (human)Ki5.45050.00071.56739.9010AID198194; AID198370
Retinoic acid receptor gamma Homo sapiens (human)Ki9.95050.00001.997510.0000AID198707; AID198734
Retinoic acid receptor RXR-alphaHomo sapiens (human)IC50 (µMol)0.00800.00600.44502.4000AID199325
Retinoic acid receptor RXR-alphaHomo sapiens (human)Ki0.01130.00040.56927.6320AID199352; AID199494; AID199646
Retinoic acid receptor RXR-betaHomo sapiens (human)Ki0.04130.00050.15920.8810AID199652; AID199814
Retinoic acid receptor RXR-betaMus musculus (house mouse)Ki3.51503.51503.51503.5150AID199314
Retinoic acid receptor RXR-gammaHomo sapiens (human)Ki0.01200.00140.15261.0000AID199189; AID199816
Retinoic acid receptor RXR-betaRattus norvegicus (Norway rat)Ki0.02000.00900.01450.0200AID199798
Retinoic acid receptor RXR-alphaRattus norvegicus (Norway rat)Ki0.01800.00300.01050.0180AID199623
Retinoic acid receptor, alpha Rattus norvegicus (Norway rat)Ki1.00002.74502.74502.7450AID197916
Retinoic acid receptor RXR-gammaRattus norvegicus (Norway rat)Ki0.01800.01200.01500.0180AID199956
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinoic acid receptor RXR-alphaHomo sapiens (human)EC50 (µMol)0.02200.00010.34279.1000AID199353; AID199482; AID47191; AID47375; AID728319
Retinoic acid receptor RXR-alphaHomo sapiens (human)Kd0.00300.00040.58388.8000AID199490
Retinoic acid receptor RXR-betaMus musculus (house mouse)EC50 (µMol)0.00300.00300.27821.2110AID199787
Retinoic acid receptor RXR-betaMus musculus (house mouse)Kd0.00300.00300.19691.0000AID199793
Retinoic acid receptor RXR-gammaMus musculus (house mouse)EC50 (µMol)0.00400.00400.19000.9610AID199946
Retinoic acid receptor RXR-gammaMus musculus (house mouse)Kd0.00300.00300.08300.3500AID199952
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)0.07250.00000.992210.0000AID47191; AID47374; AID47377
Retinoic acid receptor RXR-alphaRattus norvegicus (Norway rat)EC50 (µMol)0.01100.01100.25020.8200AID199618
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinoic acid receptor alphaHomo sapiens (human)Synergy0.00690.00190.00440.0069AID47381
Retinoic acid receptor RXR-alphaHomo sapiens (human)Efficacy0.04350.00400.04380.0840AID47378; AID47379
5-hydroxytryptamine receptor 2CHomo sapiens (human)Synergy0.00690.00190.00440.0069AID47381
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (162)

Processvia Protein(s)Taxonomy
ureteric bud developmentRetinoic acid receptor alphaHomo sapiens (human)
neural tube closureRetinoic acid receptor alphaHomo sapiens (human)
liver developmentRetinoic acid receptor alphaHomo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor alphaHomo sapiens (human)
growth plate cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
protein phosphorylationRetinoic acid receptor alphaHomo sapiens (human)
germ cell developmentRetinoic acid receptor alphaHomo sapiens (human)
female pregnancyRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of translationRetinoic acid receptor alphaHomo sapiens (human)
hippocampus developmentRetinoic acid receptor alphaHomo sapiens (human)
prostate gland developmentRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of granulocyte differentiationRetinoic acid receptor alphaHomo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor alphaHomo sapiens (human)
regulation of myelinationRetinoic acid receptor alphaHomo sapiens (human)
response to estradiolRetinoic acid receptor alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of type II interferon productionRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of tumor necrosis factor productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-13 productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-4 productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-5 productionRetinoic acid receptor alphaHomo sapiens (human)
response to vitamin ARetinoic acid receptor alphaHomo sapiens (human)
response to cytokineRetinoic acid receptor alphaHomo sapiens (human)
multicellular organism growthRetinoic acid receptor alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
regulation of apoptotic processRetinoic acid receptor alphaHomo sapiens (human)
apoptotic cell clearanceRetinoic acid receptor alphaHomo sapiens (human)
response to ethanolRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of T-helper 2 cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of neuron differentiationRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of cell cycleRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of DNA-templated transcriptionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
regulation of synaptic plasticityRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of bindingRetinoic acid receptor alphaHomo sapiens (human)
ventricular cardiac muscle cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
Sertoli cell fate commitmentRetinoic acid receptor alphaHomo sapiens (human)
limb developmentRetinoic acid receptor alphaHomo sapiens (human)
face developmentRetinoic acid receptor alphaHomo sapiens (human)
trachea cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
chondroblast differentiationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
cellular response to lipopolysaccharideRetinoic acid receptor alphaHomo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor alphaHomo sapiens (human)
cellular response to estrogen stimulusRetinoic acid receptor alphaHomo sapiens (human)
regulation of hematopoietic progenitor cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionRetinoic acid receptor alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
ureteric bud developmentRetinoic acid receptor betaHomo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor betaHomo sapiens (human)
growth plate cartilage developmentRetinoic acid receptor betaHomo sapiens (human)
apoptotic processRetinoic acid receptor betaHomo sapiens (human)
signal transductionRetinoic acid receptor betaHomo sapiens (human)
striatum developmentRetinoic acid receptor betaHomo sapiens (human)
neurogenesisRetinoic acid receptor betaHomo sapiens (human)
regulation of myelinationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor betaHomo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor betaHomo sapiens (human)
multicellular organism growthRetinoic acid receptor betaHomo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor betaHomo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor betaHomo sapiens (human)
embryonic digestive tract developmentRetinoic acid receptor betaHomo sapiens (human)
ventricular cardiac muscle cell differentiationRetinoic acid receptor betaHomo sapiens (human)
neural precursor cell proliferationRetinoic acid receptor betaHomo sapiens (human)
stem cell proliferationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor betaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor betaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor betaHomo sapiens (human)
cell differentiationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
neural tube closureRetinoic acid receptor gamma Homo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor gamma Homo sapiens (human)
growth plate cartilage chondrocyte growthRetinoic acid receptor gamma Homo sapiens (human)
apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
regulation of cell sizeRetinoic acid receptor gamma Homo sapiens (human)
anterior/posterior pattern specificationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of gene expressionRetinoic acid receptor gamma Homo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor gamma Homo sapiens (human)
regulation of myelinationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor gamma Homo sapiens (human)
response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
multicellular organism growthRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of programmed cell deathRetinoic acid receptor gamma Homo sapiens (human)
regulation of myeloid cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
canonical Wnt signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
face developmentRetinoic acid receptor gamma Homo sapiens (human)
trachea cartilage developmentRetinoic acid receptor gamma Homo sapiens (human)
prostate gland epithelium morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
Harderian gland developmentRetinoic acid receptor gamma Homo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cellular response to leukemia inhibitory factorRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cholesterol effluxRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transporter activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-alphaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-alphaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-alphaHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-betaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-betaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-gammaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-gammaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (53)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activityRetinoic acid receptor alphaHomo sapiens (human)
transcription coactivator bindingRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor alphaHomo sapiens (human)
chromatin bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor alphaHomo sapiens (human)
signaling receptor bindingRetinoic acid receptor alphaHomo sapiens (human)
protein bindingRetinoic acid receptor alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor alphaHomo sapiens (human)
protein domain specific bindingRetinoic acid receptor alphaHomo sapiens (human)
chromatin DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
histone deacetylase bindingRetinoic acid receptor alphaHomo sapiens (human)
protein kinase B bindingRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor alphaHomo sapiens (human)
mRNA 5'-UTR bindingRetinoic acid receptor alphaHomo sapiens (human)
protein kinase A bindingRetinoic acid receptor alphaHomo sapiens (human)
alpha-actinin bindingRetinoic acid receptor alphaHomo sapiens (human)
heterocyclic compound bindingRetinoic acid receptor alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor betaHomo sapiens (human)
DNA bindingRetinoic acid receptor betaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor betaHomo sapiens (human)
protein-containing complex bindingRetinoic acid receptor betaHomo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor betaHomo sapiens (human)
heterocyclic compound bindingRetinoic acid receptor betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor betaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor betaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor gamma Homo sapiens (human)
DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
chromatin bindingRetinoic acid receptor gamma Homo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor gamma Homo sapiens (human)
protein bindingRetinoic acid receptor gamma Homo sapiens (human)
zinc ion bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor gamma Homo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear receptor activityRetinoic acid receptor gamma Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
vitamin D response element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription coregulator bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
peptide bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
identical protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear vitamin D receptor bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA binding domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
LBD domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
molecular condensate scaffold activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nucleusRetinoic acid receptor alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor alphaHomo sapiens (human)
nucleolusRetinoic acid receptor alphaHomo sapiens (human)
cytoplasmRetinoic acid receptor alphaHomo sapiens (human)
cytosolRetinoic acid receptor alphaHomo sapiens (human)
plasma membraneRetinoic acid receptor alphaHomo sapiens (human)
actin cytoskeletonRetinoic acid receptor alphaHomo sapiens (human)
dendriteRetinoic acid receptor alphaHomo sapiens (human)
perinuclear region of cytoplasmRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor alphaHomo sapiens (human)
chromatinRetinoic acid receptor alphaHomo sapiens (human)
protein-containing complexRetinoic acid receptor alphaHomo sapiens (human)
nucleusRetinoic acid receptor alphaHomo sapiens (human)
nucleusRetinoic acid receptor betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor betaHomo sapiens (human)
cytoplasmRetinoic acid receptor betaHomo sapiens (human)
chromatinRetinoic acid receptor betaHomo sapiens (human)
nucleusRetinoic acid receptor betaHomo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
nucleoplasmRetinoic acid receptor gamma Homo sapiens (human)
cytoplasmRetinoic acid receptor gamma Homo sapiens (human)
membraneRetinoic acid receptor gamma Homo sapiens (human)
chromatinRetinoic acid receptor gamma Homo sapiens (human)
transcription regulator complexRetinoic acid receptor gamma Homo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
nucleusRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
mitochondrionRetinoic acid receptor RXR-alphaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-alphaHomo sapiens (human)
receptor complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
nucleusRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleolusRetinoic acid receptor RXR-betaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-betaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-betaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
cytoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (99)

Assay IDTitleYearJournalArticle
AID1346768Human Retinoid X receptor-alpha (2B. Retinoid X receptors)2000Current pharmaceutical design, Jan, Volume: 6, Issue:1
Therapeutic applications for ligands of retinoid receptors.
AID1346768Human Retinoid X receptor-alpha (2B. Retinoid X receptors)1996Nature, Oct-03, Volume: 383, Issue:6599
Activation of specific RXR heterodimers by an antagonist of RXR homodimers.
AID1346768Human Retinoid X receptor-alpha (2B. Retinoid X receptors)1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID55968In vivo hypoglycemic activity, as reduced plasma glucose in db/db mouse type II diabetes model2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID47198Synergistic efficacy against RXR:PPAR-gamma heterodimer was determined in vitro2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID728317Activation of human RXRalpha activity expressed in COS1 cells assessed as induction ratio after 12 hrs by RXRE-luciferase reporter gene assay relative to untreated control2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.
AID199648In vitro evaluation against RXR-alpha/PPAR-gamma in CV-1 cells by cotransfection assay.2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199482Inhibition of Retinoic acid receptor RXR-alpha agonist activity in vitro2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID199946Ability to activate gene expression at Retinoic acid receptor RXR-gamma was evaluated in a cotransfection assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID199618In vitro transcriptional activation in CV-1 cells expressing RXR-alpha2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199324In vitro agonist efficacy at human Retinoic X receptor alpha expressed in CV1 cells.2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID199793Binding affinity to Retinoic acid receptor RXR-beta was determined in a competitive binding assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID199623Binding affinity for Retinoic acid receptor RXR-alpha was determined by competing with 3[H]-9-cis-RA2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID728318Cytotoxicity against African green monkey COS1 cells assessed as cell survival2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.
AID220375Hypoglycemic activity in db/db mouse model after 7 days at 10 mg/kg/day oral dose2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID197916Binding affinity for Retinoic acid receptor alpha was determined by competing with 3[H]-ATRA2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID47375In vitro agonistic activity against RXR alpha in CV-1 cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID728319Activation of human RXRalpha activity expressed in COS1 cells after 12 hrs by RXRE-luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.
AID199798Binding affinity for Retinoic acid receptor RXR-beta was determined by competing with 3[H]-9-cis-RA2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID47374In vitro agonist efficacy against PPAR gamma along with 100 nM BRL-496532003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID199321Agonist activity for Retinoic X receptor alpha in CV1 cells2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID198194Binding affinity against RAR beta receptor using [3H]ATRA as radioligand in CV-1 cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID199494Binding affinity against Retinoic acid receptor RXR-alpha was determined in vitro by using [3H]9-cis-RA as radioligand2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID199650In vitro evaluation against RXR-alpha/PPAR-gamma in CV-1 cells by cotransfection assay was determined2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199323In vitro agonist efficacy at human Retinoic X receptor alpha expressed in CV1 cells.2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID199490Ability to bind directly to Retinoic acid receptor RXR-alpha was evaluated in a competitive binding assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID199325Antagonist activity for Retinoic X receptor alpha in CV1 cells2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID199352Binding affinity against RXR alpha receptor using [3H]9-cis-RA as radioligand in CV-1 cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID204505Effect on T4 levels in male Dawley rats at 24 hr r2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID198894Binding affinity for Retinoic acid receptor gamma was determined by competing with 3[H]-ATRA2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199619In vitro transcriptional activation in CV-1 cells expressing RXR-alpha2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199621In vitro transcriptional activation in CV-1 cells expressing RXR-alpha2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199504Inhibition of Retinoic acid receptor RXR-alpha antagonist activity in vitro; Not calculated2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID157284Binding affinity for Peroxisome proliferator activated receptor gamma was determined2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID189944T4 level in rats at 24 hr r after 30 mg/kg oral dose2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199353Ability to activate gene expression at Retinoic acid receptor RXR-alpha was evaluated in a cotransfection assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID199488Antagonistic efficacy against Retinoic acid receptor RXR-alpha was determined in vitro2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID198370Binding affinity for Retinoic acid receptor beta was determined by competing with 3[H]-ATRA2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199952Binding affinity to Retinoic acid receptor RXR-gamma was evaluated in a competitive binding assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID199816Binding affinity against RXR gamma receptor using [3H]9-cis-RA as radioligand in CV-1 cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID47377In vitro agonistic activity against PPAR gamma along with 100 nM BRL-496532003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID47180Transcriptional activation in CV-1 cells expressing RXR and LXR at 1 uM2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID199314Binding affinity against retinoic acid receptor beta by [3H]ATRA displacement.2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID204506Effect on triglyceride level in male Dawley rats at 24 hr r2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID199189Displacement of [3H]9-cis-RA from retinoic X receptor gamma2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID47191Transcriptional activity against RXR:PPAR-gamma synergy was determined in vitro2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID199486Agonistic efficacy against Retinoic acid receptor RXR-alpha was determined in vitro2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID47379In vitro antagonist efficacy against RXR alpha in CV-1 cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID199956Binding affinity for Retinoic acid receptor RXR-gamma was determined by competing with 3[H]-9-cis-RA2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199341In vitro synergistic elevation of transcriptional activation in CV-1 cells expressing RAR and RXR with 3 nm TTNBP2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199977Binding affinity against RAR alpha receptor using [3H]ATRA as radioligand in CV-1 cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID199194Binding affinity against retinoic acid receptor alpha by [3H]ATRA displacement.2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID47381Agonist synergy against RAR alpha was tested along with 3 nM TTNPB2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID191968Triglyceride level in rats 24 hr r after 30 mg/kg oral dose2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID47378In vitro agonist efficacy against RXR alpha in CV-1 cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID198707Binding affinity against RAR gamma receptor using [3H]ATRA as radioligand in CV-1 cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID199646Binding affinity against Retinoic acid receptor RXR-alpha by [3H]9-cis-RA displacement.2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID234577RXR:RAR synergy expressed as fold induction2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID199315Binding affinity against retinoic acid receptor gamma by [3H]ATRA displacement.2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID199814Displacement of [3H]9-cis-RA from Retinoic X receptor beta2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
AID156458Binding affinity for Peroxisome proliferator activated receptor alpha was determined2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199787Ability to activate gene expression at Retinoic acid receptor RXR-beta was evaluated in a cotransfection assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID55969In vivo hypoglycemic activity compared to BRL-46953 as reduced plasma glucose in db/db mouse type II diabetes model2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID198734Binding affinity against Retinoic acid receptor gamma was determined in vitro by using [3H]ATRA as radioligand2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
AID199647In vitro evaluation against RXR-alpha/PPAR-gamma in CV-1 cells by cotransfection assay was determined2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
AID199652Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (107)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (13.08)18.2507
2000's60 (56.07)29.6817
2010's26 (24.30)24.3611
2020's7 (6.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.96 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other106 (98.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]